BIO President Jim Greenwood Says Indian Biosimilars Welcome In U.S. Market: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Greenwood recently returned from a barnstorming trip across India to drum up interest for the BIO India Partnering Conference in September 2010. He spoke with PharmAsia News about partnering prospects, regulatory concerns and potential roadblocks for India's biotech growth.
You may also be interested in...
Jim Greenwood Says BIO Welcomes Biosimilars; Clarity On Non-inferiority Trials For Substitutability Of Biotech Drugs May Come Up Next Year
MUMBAI - The entry of biosimilars into the U.S. market will be welcomed by the biotech industry, Jim Greenwood, CEO of the Biotechnology Industry Organization, which represents multinational biotech companies, told the recent BioInvest conference in Mumbai
Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.